NUCLEAR PHARMACY CONFERENCE-PHARMACIST
Saturday, October 7, 2023
Pharmacy and Therapeutics Formulary Process, A Case Study on Sincalide
8:00am-9:30am
Jacob Haddock, PharmD, ANP, Oklahoma University Medical Center, Clinical Pharmacist
Upon completion of this activity, pharmacists will be able to: Describe the function and oversight of the pharmacy and therapeutics (P&T) committee; Provide information required by the pharmacy director to add a generic to the formulary; Evaluate a medication for inclusion in the formulary using the example provided.
UAN: 0675-0000-23-017-L04-P
Primer on Potential Theragnostic Agents
9:30am-11:00am
Wendy Galbraith, PharmD, FAPhA, BCNP, Clinical Associate Professor, University of Oklahoma, Dept. of Pharmaceutical Sciences, College of Pharmacy, Nuclear Pharmacy & Research Imaging Facility
Upon completion of this activity, pharmacists will be able to: Recall radionuclides for therapy; Describe regulations for therapy radiopharmaceuticals; Identify new radiopharmaceutical therapies in the pipeline.
UAN: 0675-0000-23-018-L04-P
Nuclear Pharmacy: Departments Questions when 795, 797, and 825 are Official – PART 1
11:15am-12:45pm
Jessica Comstock, PharmD, BCNP, Vice President Pharmacy Quality and Regulatory, PharmaLogic Holdings
Upon completion of this activity, pharmacists will be able to: Describe the changes taking place with the implementation of USP 825, 797, and 795; Identify the additional USP chapters that are applicable to nuclear pharmacy; Describe how internal procedures and parameters are determined and why they matter.
UAN: 0675-0000-23-019-L07-P
Sterile Preparation of I-131 Solution for Feline Hyperthyroidism
12:45pm-2:15pm
Garcia Simon, PharmD, MS, ANP, CCP, BCNP, Kindred Healthcare, Pharmacy Supervisor
Upon completion of this activity, pharmacists will be able to: Describe the treatments available for feline hyperthyroidism; Identify the methods of administration of I-131 solution; Discuss the preparation method of the sterile solution applying principles of radiation safety.
UAN: 0675-0000-23-020-L01-P
Sunday, October 8, 2023
Review of the Principles Related to Scintillation Detection of Radioactive Materials
8:00am-9:30am N/G
Kara Weatherman, PharmD, FAPhA, BCNP, Clinical Professor & Associate Department Head - Department of Pharmacy Practice, Director – Nuclear Pharmacy Programs, Purdue University
Upon completion of this activity, pharmacists will be able to: Review basic principles of setting up and operating a scintillation detector; Discuss the differences between single and multi-channel detectors; Describe the concept of efficiency and how this relates to accurate determination of radioactivity.
UAN: 0675-0000-23-016-L04-P
F-18 Flurpiridaz Assessment of Myocardial Perfusion-Specific Procedures
9:30am-11:00am
Wendy Galbraith, PharmD, FAPhA, BCNP, Clinical Associate Professor, University of Oklahoma, Dept. of Pharmaceutical Sciences, College of Pharmacy, Nuclear Pharmacy & Research Imaging Facility
Upon completion of this activity, pharmacists will be able to: Recall the properties of PET and SPECT MPI tracers; Describe the PET imaging technology used for myocardial imaging; Identify clinical applications for F-18 flurpiridaz.
UAN: 0675-0000-23-021-L01-P
Nuclear Pharmacy: Department Questions when 795, 797, and 825 are Official – PART 2
11:15am-12:45pm
Jessica Comstock, PharmD, BCNP, Vice President Pharmacy Quality and Regulatory, PharmaLogic Holdings
Upon completion of this activity, pharmacists will be able to: Describe the changes taking place with the implementation of USP 825, 797, and 795; Identify the additional USP chapters that are applicable to nuclear pharmacy; Discuss how internal procedures and parameters are determined and why they matter.
UAN: 0675-0000-23-022-L07-P
Pharmacist’s Potential Role in Radiopharmaceutical Therapy (RPT)
12:45pm-2:15pm
Reiko Oyama, MS, RPH, BCNP, Washington University, Director, Nuclear Pharmacy
Upon completion of this activity, pharmacists will be able to: Describe logistical, technical, and radiation safety considerations for implementing a radiopharmaceutical therapy program; List major operating procedures for the RPT example Lu-177-PSMA; Develop your own plan for implementing a radiopharmaceutical therapy program.
UAN: 0675-0000-23-023-L04-P
No Comments